SNHG12 and glioma: Furthermore, increasing evidence suggests that overexpression of SNHG12 is linked to a poor prognosis or a high risk of clinicopathological characteristics in osteosarcoma [14], nasopharyngeal carcinoma, NSCLC [15], gastric carcinoma, hepatocellular carcinoma, glioma, cervical cancer, colorectal cancer, and triple-negative breast cancer [16-22].